Factor Xa inhibitors in the prevention and treatment of venous thromboembolism - The role of fondaparinux, first of a new class of antithrombotic agents

Fondaparinux is a novel antithrombotic agent, which has a number of properties that distinguish it from existing therapies (LMWHs and unfractionated heparin) for the prophylaxis and treatment of VTE. • Fondaparinux is the first in a new class of selective factor Xa inhibitors, with a unique mode of action. • Fondaparinux is an entirely synthetic, single-chemical entity, not derived from animal sources. • Fondaparinux has a pharmacokinetic …